Drugs / IS-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04574401 | Oct 2020 → Sep 2021 | prostate cancer | Intuitive Surgical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05946603 | Jun 2023 → May 2024 | prostate cancer | Intuitive Surgical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IS-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05946603 ↗ |
| Modality | Diagnostic / imaging agent | “for fluorescent identification and delineation of the positive cancer margins and metastatic lymph nodes during prostatectomy surgery” NCT04574401 ↗ |
| Route | Intravenous | “IS-002 intravenous (IV) injection” NCT04574401 ↗ |